On April 23rd, the Intellectual Property Court of the Supreme People’s Court held a simultaneous hearing, publicly hearing the appeal cases of standard patent infringement for
Recently, Hangzhou Adcoris Biopharmaceutical Co., Ltd. and international biopharmaceutical company K2 Therapeutics reached a global exclusive strategic cooperation on the First in class ADC candidate drug
On April 22nd, QLS7320 injection, a Class 1 innovative drug independently developed by Qilu Pharmaceutical, officially obtained implied clinical trial approval from the Center for Drug
This article summarizes the mandatory requirements and writing rules for full disclosure from four aspects: chemical products, preparation methods, application inventions, and implementation examples, providing practical
On April 9th, the United States Patent and Trademark Office (USPTO) issued a notice in the Federal Register officially implementing the PCT Informed Examination Request (PIER)
At present, the biopharmaceutical industry is entering a golden period of development, with continuous breakthroughs in cutting-edge technologies and innovative projects with core barriers and clear
· National Intellectual Property Administration Holds Open Day Event · Jiangxi Intellectual Property Office Signs Strategic Cooperation Agreement with Beijing Center for Patent Examination Cooperation of
In recent years, the hottest and most capital concentrated track in the global biopharmaceutical field is undoubtedly antibody conjugated drugs (ADCs). From cross-border pharmaceutical enterprises’ high
On April 9th, the United States Patent and Trademark Office (USPTO) issued a notice in the Federal Register officially implementing the PCT Informed Examination Request (PIER)
This round of information summarizes 6 innovative enterprises, among which Xingrui Pharmaceutical has completed a B+round of financing focusing on RNA drug research and development, Feimou